Novanta (NOVT) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $244.4 million, up 10.3% year-over-year, driven by acquisitions, favorable currency impact, and strong new product momentum despite a challenging macroeconomic environment.

• Net income for Q3 2024 was $19.2 million, down from $21.2 million in Q3 2023, primarily due to higher interest and tax expenses.

• Adjusted EBITDA increased to $57 million, with a 23% margin, and customer bookings grew 13% year-over-year, especially in minimally invasive surgery products.

• Integration of the Motion Solutions acquisition is on track, contributing to Medical Solutions growth and expanding the acquisition pipeline.

• For the nine months ended September 27, 2024, revenue grew 6.1% to $711.2 million, with net income of $47.6 million.

Financial highlights

• Q3 2024 revenue was $244.4 million, up 10.3% year-over-year, with organic growth flat and most gains from acquisitions.

• Adjusted gross margin was 46%; GAAP gross margin was 44.7%, down from 45.9% in Q3 2023.

• Adjusted EBITDA was $57 million, up 9% year-over-year, with a 23% margin.

• Operating cash flow for Q3 was $23 million, down from $44.6 million in Q3 2023; year-to-date operating cash flow was $97 million, up from $81.1 million.

• Net debt increased to $368 million, with total debt at $457.5 million and cash and cash equivalents at $92.7 million.

Outlook and guidance

• Q4 2024 revenue expected at $237–$242 million (12–14% reported growth, 2–4% organic); full-year 2024 revenue at $948–$953 million (8% reported growth).

• Adjusted gross margin for Q4 and full year expected at 46%.

• Adjusted EBITDA for Q4 expected at $50–$52 million; full year at $208–$210 million.

• Adjusted EPS for Q4 expected at $0.70–$0.74; full year at $3.02–$3.06.

• Organic revenue growth of up to 10% projected for 2025, with strong double-digit growth in the second half.